<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Striatal Medium Spiny Neurons in Huntington's Disease</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Striatal Medium Spiny Neurons in Huntington's Disease</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Cell Type</td>
</tr>
</table>
Striatal medium spiny neurons (MSNs) are the principal neuronal population destroyed in [Huntington's disease (HD)](https://pubmed.ncbi.nlm.nih.gov/3179951/), representing approximately 95% of the neurons in the striatum. These GABAergic projection neurons are the primary efferent output of the basal ganglia, integrating cortical excitation and modulatory dopamine signals to coordinate movement, habit formation, and procedural learning. The selective vulnerability of MSNs to mutant huntingtin (mHTT) toxicity makes them the central pathological target in HD, explaining the characteristic choreiform movements, cognitive decline, and psychiatric symptoms that define the disease phenotype.
<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Striatal Medium Spiny Neurons in Huntington's Disease</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Striatal Medium Spiny Neurons in Huntington's Disease</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Cell Type</td>
</tr>
</table>
Striatal medium spiny neurons (MSNs) are the principal neuronal population destroyed in [Huntington's disease (HD)](https://pubmed.ncbi.nlm.nih.gov/3179951/), representing approximately 95% of the neurons in the striatum. These GABAergic projection neurons are the primary efferent output of the basal ganglia, integrating cortical excitation and modulatory dopamine signals to coordinate movement, habit formation, and procedural learning. The selective vulnerability of MSNs to mutant huntingtin (mHTT) toxicity makes them the central pathological target in HD, explaining the characteristic choreiform movements, cognitive decline, and psychiatric symptoms that define the disease phenotype.
The degeneration of MSNs in Huntington's disease represents one of the most striking examples of selective neuronal vulnerability in neurodegenerative disorders.[@pmid19143656] Unlike the widespread protein aggregation seen in [Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/1459769/) or [Parkinson's disease](https://pubmed.ncbi.nlm.nih.gov/2594458/), HD demonstrates a remarkably specific pattern of neuronal loss centered on the striatum, with particular devastation to the indirect pathway MSNs expressing the [D2 dopamine receptor](https://pubmed.ncbi.nlm.nih.gov/1673392/). This selective vulnerability has motivated decades of research into the molecular mechanisms underlying MSN degeneration, revealing a complex interplay of transcriptional dysregulation, mitochondrial dysfunction, excitotoxicity, and impaired protein homeostasis that continues to drive therapeutic development.
The striatum, composed of the [caudate nucleus](https://en.wikipedia.org/wiki/Caudate_nucleus) and [putamen](https://en.wikipedia.org/wiki/Putamen), serves as the primary input gateway to the basal ganglia. Medium spiny neurons constitute the sole output of the striatum, projecting via the direct and indirect pathways to regulate thalamocortical activity and motor output. The direct pathway (D1-MSNs) facilitates movement through disinhibition of thalamocortical circuits, while the indirect pathway (D2-MSNs) suppresses competing motor programs to enable smooth, coordinated movement. This delicate balance is disrupted early in HD, with D2-MSNs showing particular vulnerability even before overt symptom onset, accounting for the characteristic motor abnormalities that define the prodromal and early manifest phases of the disease.
MSNs project to distinct downstream targets that define their functional role in motor control. Direct pathway D1-MSNs send inhibitory projections to the [substantia nigra pars reticulata](https://en.wikipedia.org/wiki/Substantia_nigra) (SNr) and [internal segment of the globus pallidus](https://en.wikipedia.org/wiki/Globus_pallidus) (GPi), ultimately disinhibiting thalamic motor nuclei. Indirect pathway D2-MSNs project to the [external segment of the globus pallidus](https://en.wikipedia.org/wiki/Globus_pallidus) (GPe), creating an indirect inhibitory circuit that modulates motor output through the subthalamic nucleus and SNr. The loss of MSN projections disrupts these canonical circuits, leading to the hyperkinetic movements (chorea) in early HD and the hypokinetic features (bradykinesia, rigidity) in advanced disease.
The causative mutation in Huntington's disease is an expanded CAG repeat tract in the [HTT gene](https://pubmed.ncbi.nlm.nih.gov/7649584/), encoding a polyglutamine tract in the huntingtin protein that triggers toxic gain-of-function and loss-of-normal function mechanisms. Mutant huntingtin (mHTT) forms intracellular aggregates that sequester essential transcriptional regulators, including [CREB-binding protein (CBP)](https://pubmed.ncbi.nlm.nih.gov/10436043/) and [p53](https://pubmed.ncbi.nlm.nih.gov/2468192/), disrupting gene expression programs critical for neuronal survival. The aggregation of mHTT into inclusion bodies represents a pathological hallmark, though the relationship between inclusion formation and neuronal dysfunction remains complex, with evidence suggesting that soluble oligomeric species may be more toxic than large aggregates.
One of the earliest and most pervasive consequences of mHTT expression is widespread transcriptional dysregulation.[@pmid19794415] Mutant huntingtin directly interacts with transcription factors including [REST](https://pubmed.ncbi.nlm.nih.gov/10593514/), [NCOR1](https://pubmed.ncbi.nlm.nih.gov/10958687/), and [p53](https://pubmed.ncbi.nlm.nih.gov/2468192/), altering the expression of genes essential for neuronal function, synaptic plasticity, and survival. The downregulation of [PGC-1α](https://pubmed.ncbi.nlm.nih.gov/17635942/) (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) is particularly significant, as this master regulator of mitochondrial biogenesis controls the expression of genes involved in oxidative phosphorylation, antioxidant defense, and mitochondrial dynamics. Loss of PGC-1α function compromises mitochondrial function and cellular energy metabolism, creating a permissive environment for neurodegeneration.[@pmid23448445]
Mitochondrial abnormalities are among the most consistently observed pathologies in HD patient brains and cellular models.[@pmid26561400] Complex I, II, and IV activities are reduced in striatal tissue from HD patients and mouse models, leading to impaired ATP production and increased reactive oxygen species (ROS) generation. The preferential sensitivity of striatal neurons to mitochondrial toxins such as 3-nitropropionic acid demonstrates the particular vulnerability of these cells to bioenergetic compromise. Mitochondrial dysfunction in MSNs involves impaired calcium buffering, disrupted mitochondrial trafficking along microtubules, and defective mitophagy, the autophagy pathway responsible for removing damaged mitochondria.
Striatal MSNs are particularly vulnerable to glutamate-induced excitotoxicity due to their high density of [NMDA-type glutamate receptors](https://pubmed.ncbi.nlm.nih.gov/7515896/) and relative deficiency in calcium-buffering proteins compared to cortical neurons. Mutant huntingtin disrupts presynaptic release machinery, leading to increased glutamate release from corticostriatal afferents, while simultaneously impairing postsynaptic signaling and astrocytic glutamate uptake. The resulting calcium overload activates downstream death pathways including calpain-mediated proteolysis, mitochondrial permeabilization, and caspase activation. NMDA receptor antagonists have shown neuroprotective effects in HD models, though clinical translation has been limited by unacceptable side effect profiles.
Beyond acute excitotoxic injury, chronic synaptic dysfunction develops progressively in HD MSNs. Dendritic spine loss, particularly on D2-MSNs, occurs early in disease progression and correlates with cognitive deficits. Synaptic alterations include reduced amplitude of excitatory postsynaptic currents, impaired long-term potentiation (LTP), and disrupted corticostriatal integration. The extracellular matrix surrounding MSNs also contributes to vulnerability, with alterations in perineuronal nets and matrix metalloproteinases influencing neuronal survival.
The differential vulnerability of D1- and D2-expressing MSNs represents a fundamental feature of HD pathophysiology. D2-MSNs of the indirect pathway show earlier and more severe degeneration, contributing to the characteristic motor dysregulation in HD. This selective vulnerability reflects differences in transcriptional programs, calcium handling, mitochondrial biology, and synaptic inputs between these subpopulations. D1-MSNs express higher levels of brain-derived neurotrophic factor ([BDNF](https://pubmed.ncbi.nlm.nih.gov/8626557/)) and demonstrate greater resilience to oxidative stress, while D2-MSNs exhibit heightened sensitivity to metabolic challenges.
Astrocytes play critical supportive roles in striatal circuitry, and their dysfunction contributes significantly to MSN degeneration. Astrocytic [mGluR5](https://pubmed.ncbi.nlm.nih.gov/10676956/) signaling influences striatal microcircuits, with altered calcium signaling affecting glutamate uptake and metabolic support. In HD, astrocytes expressing mutant huntingtin show impaired potassium buffering, reduced glutamate uptake, and compromised metabolic coupling with neurons. These glial defects compound neuronal vulnerability, creating a non-cell-autonomous component to HD pathogenesis that offers potential therapeutic targets.
Recent advances in cellular reprogramming have enabled the generation of HD patient-derived MSNs through direct conversion of fibroblasts and differentiation of induced pluripotent stem cells (iPSCs). These models recapitulate age-associated disease phenotypes including mitochondrial dysfunction, transcriptional alterations, and progressive degeneration. Three-dimensional striato-nigral assembloids have been developed to model the projection defects characteristic of HD, providing novel platforms for drug screening. Patient-derived neurons demonstrate CAG repeat length-dependent phenotypes and offer opportunities for personalized therapeutic approaches.
The CAG repeat expansion in HTT exhibits tissue-specific and neuron-specific somatic instability, with striatal neurons showing particularly dramatic repeat expansion during disease progression. Recent research has identified distinct mismatch repair complex genes, including [MSH3](https://pubmed.ncbi.nlm.nih.gov/23953161/) and [PMS2](https://pubmed.ncbi.nlm.nih.gov/23953159/), that set neuronal CAG-repeat expansion rates and drive selective pathogenesis in HD mouse models. Genetic modification of these DNA repair proteins offers a potential approach to slow disease progression by limiting somatic repeat expansion in vulnerable neuronal populations.
Multiple therapeutic approaches targeting MSN degeneration are in development. Gene therapy strategies using [antisense oligonucleotides (ASOs)](https://en.wikipedia.org/wiki/Antisense_oligonucleotide) aim to reduce mutant huntingtin expression, with the ASO tominersen showing promise in clinical trials. Cell replacement therapies using transplanted MSNs have been explored, with evidence that newly generated striatal neurons can rescue motor circuitry in HD mouse models. Small molecules targeting mitochondrial dysfunction, excitotoxicity, and transcriptional dysregulation continue to advance through preclinical and clinical development.
The selective vulnerability of MSNs provides opportunities for biomarker development to track disease progression and therapeutic response. Neuroimaging studies using PET ligands targeting dopamine receptors, mitochondrial complex I, or synaptic markers can reveal striatal degeneration in premanifest individuals. Cerebrospinal fluid biomarkers including neurofilament light chain (NfL), total tau, and mutant huntingtin fragments show promise for monitoring disease progression and treatment response in clinical trials.
Understanding the molecular mechanisms underlying MSN vulnerability continues to inform therapeutic development. Recent work on developmental transcriptomic signatures in HD MSNs has identified cerulenin as partially correcting these disruptions, highlighting new therapeutic targets. The integration of patient-derived cellular models, genetic insights from DNA repair pathways, and advances in gene therapy positions the field to develop disease-modifying treatments targeting the core pathology in HD.